|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 6/16/22 THC Therapeutics, Inc. 10-Q 4/30/22 61:3.8M Discount Edgar/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 653K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 20K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 20K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 16K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 16K
11: R1 Cover HTML 64K
12: R2 Consolidated Balance Sheets HTML 118K
13: R3 Consolidated Balance Sheets (Parenthetical) HTML 41K
14: R4 Consolidated Statement of Operations HTML 85K
15: R5 Consolidated Statements of Stockholders Equity HTML 83K
16: R6 Consolidated Statement of Cash Flows HTML 85K
17: R7 Description of Business and History HTML 21K
18: R8 Basis of Presentation and Going Concern HTML 22K
19: R9 Summary of Significant Policies HTML 51K
20: R10 Physical Silver Assets HTML 19K
21: R11 Fixed Assets HTML 26K
22: R12 Intangible Assets HTML 25K
23: R13 Related Party Transactions HTML 38K
24: R14 Notes Payable HTML 22K
25: R15 Convertible Notes Payable HTML 63K
26: R16 Commitments and Contingencies HTML 24K
27: R17 Stock Warrants HTML 25K
28: R18 Shareholders Deficit HTML 36K
29: R19 Subsequent Events HTML 19K
30: R20 Summary of Significant Policies (Policies) HTML 74K
31: R21 Summary of Significant Policies (Tables) HTML 43K
32: R22 Fixed Assets (Tables) HTML 24K
33: R23 Intangible Assets (Tables) HTML 25K
34: R24 Related Party Transactions (Tables) HTML 36K
35: R25 Notes Payable (Tables) HTML 21K
36: R26 Convertible Notes Payable (Tables) HTML 63K
37: R27 Stock Warrants (Tables) HTML 26K
38: R28 Basis of Presentation and Going Concern (Details HTML 39K
Narrative)
39: R29 Summary of Significant Policies (Details ) HTML 25K
40: R30 Summary of Significant Policies (Details 1) HTML 22K
41: R31 Summary of Significant Policies (Details HTML 31K
Narrative)
42: R32 Physical Silver Assets (Details Narrative) HTML 17K
43: R33 Fixed Assets (Details) HTML 28K
44: R34 Fixed Assets (Details Narrative) HTML 18K
45: R35 Intangible Assets (Details) HTML 26K
46: R36 Intangible Assets (Details Narrative) HTML 18K
47: R37 Related Party Transactions (Details) HTML 27K
48: R38 Related Party Transactions (Details 1) HTML 26K
49: R39 Related Party Transactions (Details Narrative) HTML 43K
50: R40 Notes Payable (Details) HTML 21K
51: R41 Notes Payable (Details Narrative) HTML 21K
52: R42 Convertible Notes Payable (Details) HTML 38K
53: R43 Convertible Notes Payable (Details 1) HTML 26K
54: R44 Commitments and Contingencies (Details Narrative) HTML 20K
55: R45 Stock Warrants (Details) HTML 36K
56: R46 Shareholders Deficit (Details Narrative) HTML 138K
59: XML IDEA XML File -- Filing Summary XML 104K
57: XML XBRL Instance -- thct_10q_htm XML 983K
58: EXCEL IDEA Workbook of Financial Reports XLSX 63K
8: EX-101.CAL XBRL Calculations -- thct-20220430_cal XML 114K
10: EX-101.DEF XBRL Definitions -- thct-20220430_def XML 302K
7: EX-101.LAB XBRL Labels -- thct-20220430_lab XML 585K
9: EX-101.PRE XBRL Presentations -- thct-20220430_pre XML 473K
6: EX-101.SCH XBRL Schema -- thct-20220430 XSD 142K
60: JSON XBRL Instance as JSON Data -- MetaLinks 228± 297K
61: ZIP XBRL Zipped Folder -- 0001477932-22-004445-xbrl Zip 111K
EXHIBIT 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of THC Therapeutics, Inc. (the "Company") on Form 10-Q for the fiscal period ended April 30, 2022 (the "Report"), I, Brandon Romanek, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| 1) | The Report fully complies with the requirement of Section 13(a) or 15 (d) of the Securities Exchange Act of 1934; and |
| 2) | The information contained in the Report fairly presents, in all material respects, the Company's financial position and results of operations. |
| Date: June 15, 2022 | By: | /s/ Brandon Romanek |
|
|
|
|
| |
|
|
| Chief Financial Officer |
|
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 6/16/22 | None on these Dates | ||
| 6/15/22 | ||||
| For Period end: | 4/30/22 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 10/04/19 THC Therapeutics, Inc. 10-12G/A 8:1.1M Discount Edgar/FA 8/22/19 THC Therapeutics, Inc. 10-12G/A 7:1.2M Discount Edgar/FA 7/08/19 THC Therapeutics, Inc. 10-12G/A 3:983K Discount Edgar/FA 4/08/19 THC Therapeutics, Inc. 10-12G/A 4:38M Discount Edgar/FA 10/19/18 THC Therapeutics, Inc. 10-12G 10/22/18 17:17M Discount Edgar/FA |